Corrigendum to Addition of docetaxel to hormonal therapy in low- and high-burden metastatic hormone sensitive prostate cancer: long-term survival results from the STAMPEDE trial: Ann Oncol 2019; 30: 1992-2003.

Clarke, N; Ali, A; Ingleby, FORCID logo; Hoyle, A; Amos, C; Attard, G; Brawley, C; Calvert, J; Chowdhury, S; Cook, A; +41 more...Cross, W; Dearnaley, D; Douis, H; Gilbert, D; Gillessen, S; Jones, R; Langley, R; MacNair, A; Malik, Z; Mason, M; Matheson, D; Millman, R; Parker, C; Ritchie, A; Rush, H; Russell, J; Brown, J; Beesley, S; Birtle, A; Capaldi, L; Gale, J; Gibbs, S; Lydon, A; Nikapota, A; Omlin, A; O'Sullivan, J; Parikh, O; Protheroe, A; Rudman, S; Srihari, N; Simms, M; Tanguay, J; Tolan, S; Wagstaff, J; Wallace, J; Wylie, J; Zarkar, A; Sydes, M; Parmar, M; James, N; STAMPEDE investigators and (2020) Corrigendum to Addition of docetaxel to hormonal therapy in low- and high-burden metastatic hormone sensitive prostate cancer: long-term survival results from the STAMPEDE trial: Ann Oncol 2019; 30: 1992-2003. ANNALS OF ONCOLOGY, 31 (3). 442-. ISSN 0923-7534 DOI: 10.1016/j.annonc.2020.01.002
Copy

The authors regret that Fig.2F has been incorrectly titled. The correct title is “Failure-free survival high burden M1”.


picture_as_pdf
PIIS0923753420359202.pdf
subject
Published Version
Available under Creative Commons: Attribution-NonCommercial-No Derivative Works 3.0

View Download

Atom BibTeX OpenURL ContextObject in Span Multiline CSV OpenURL ContextObject Dublin Core Dublin Core MPEG-21 DIDL Data Cite XML EndNote HTML Citation JSON MARC (ASCII) MARC (ISO 2709) METS MODS RDF+N3 RDF+N-Triples RDF+XML RIOXX2 XML Reference Manager Refer Simple Metadata ASCII Citation EP3 XML
Export

Downloads